Shantanu Banerji

6.7k total citations
49 papers, 866 citations indexed

About

Shantanu Banerji is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shantanu Banerji has authored 49 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Shantanu Banerji's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (11 papers) and Cancer Genomics and Diagnostics (9 papers). Shantanu Banerji is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (11 papers) and Cancer Genomics and Diagnostics (9 papers). Shantanu Banerji collaborates with scholars based in Canada, United States and India. Shantanu Banerji's co-authors include Vallerie Gordon, Daniel E. Meyers, Don Morris, Natasha B. Leighl, Leigh C. Murphy, Barbara Melosky, David E. Dawe, Parneet Cheema, Ming‐Sound Tsao and Gefei Qing and has published in prestigious journals such as Journal of Clinical Oncology, Genes & Development and SHILAP Revista de lepidopterología.

In The Last Decade

Shantanu Banerji

44 papers receiving 855 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shantanu Banerji Canada 17 398 342 323 175 77 49 866
Hong Jian China 21 387 1.0× 365 1.1× 303 0.9× 128 0.7× 90 1.2× 50 978
Rafał Stec Poland 18 445 1.1× 303 0.9× 377 1.2× 211 1.2× 56 0.7× 61 926
Jacques Raphael Canada 15 541 1.4× 315 0.9× 187 0.6× 167 1.0× 58 0.8× 70 1.1k
Fernando Franco Spain 14 305 0.8× 211 0.6× 215 0.7× 235 1.3× 61 0.8× 44 803
Gwyn Bebb Canada 20 643 1.6× 311 0.9× 360 1.1× 157 0.9× 75 1.0× 48 1.1k
Laurence Vanlemmens France 15 675 1.7× 198 0.6× 169 0.5× 244 1.4× 52 0.7× 70 961
Shipra Gandhi United States 16 442 1.1× 177 0.5× 204 0.6× 220 1.3× 51 0.7× 89 868
Antonia Ridolfi France 15 340 0.9× 295 0.9× 193 0.6× 99 0.6× 117 1.5× 51 735
Maria Alice Franzoi France 16 568 1.4× 332 1.0× 155 0.5× 167 1.0× 45 0.6× 51 868
Keerthi Gogineni United States 17 685 1.7× 390 1.1× 235 0.7× 250 1.4× 58 0.8× 58 1.0k

Countries citing papers authored by Shantanu Banerji

Since Specialization
Citations

This map shows the geographic impact of Shantanu Banerji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shantanu Banerji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shantanu Banerji more than expected).

Fields of papers citing papers by Shantanu Banerji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shantanu Banerji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shantanu Banerji. The network helps show where Shantanu Banerji may publish in the future.

Co-authorship network of co-authors of Shantanu Banerji

This figure shows the co-authorship network connecting the top 25 collaborators of Shantanu Banerji. A scholar is included among the top collaborators of Shantanu Banerji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shantanu Banerji. Shantanu Banerji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sheffield, Brandon S., Shantanu Banerji, Shaan Dudani, et al.. (2025). Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada. Current Oncology. 32(3). 141–141.
2.
Melosky, Barbara, Rosalyn A. Juergens, Shantanu Banerji, et al.. (2025). The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 17. 12753520–12753520.
3.
Oberoi, Sapna, Allan Garland, Pascal Lambert, et al.. (2024). Mental Disorders Among Adolescents and Young Adults With Cancer: A Canadian Population–Based and Sibling Cohort Study. Journal of Clinical Oncology. 42(13). 1509–1519. 7 indexed citations
4.
Meyers, Daniel E., et al.. (2024). Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials. Current Oncology. 31(9). 5498–5515.
5.
Cheema, Parneet, Shantanu Banerji, Normand Blais, et al.. (2023). Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Current Oncology. 30(7). 6473–6496. 1 indexed citations
6.
Snow, Stephanie, Paul Wheatley‐Price, Barbara Melosky, et al.. (2023). Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology. 30(7). 6559–6574. 4 indexed citations
7.
Dawe, David E., et al.. (2023). Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study. Frontiers in Oncology. 13. 1191855–1191855. 4 indexed citations
8.
Ionescu, Diana N., Tracy Stockley, Shantanu Banerji, et al.. (2022). Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. Current Oncology. 29(7). 4981–4997. 20 indexed citations
9.
Sanusi, Ridwan A., Lin Yan, Mohammad Jafari Jozani, et al.. (2022). Transitions between versions of the International Classification of Diseases and chronic disease prevalence estimates from administrative health data: a population-based study. BMC Public Health. 22(1). 701–701. 7 indexed citations
10.
Banerji, Shantanu, Daniel E. Meyers, Craig Harlos, & David E. Dawe. (2021). The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma. Current Oncology. 28(6). 4542–4551. 4 indexed citations
11.
Simmons, Christine, Rebecca Deyell, Andrea J. MacNeill, et al.. (2021). Canadian consensus onTRK‐inhibitortherapy forNTRKfusion‐positive sarcoma. International Journal of Cancer. 149(9). 1691–1704. 4 indexed citations
12.
Bucher, Oliver, et al.. (2021). Population-based impacts of new therapies on outcomes for stage IV non-small cell lung cancer.. Journal of Clinical Oncology. 39(15_suppl). 9120–9120. 1 indexed citations
13.
Goldberg, Erin, Biniam Kidane, Julian Kim, et al.. (2021). Comparative metabolomics studies of blood collected in streck and heparin tubes from lung cancer patients. PLoS ONE. 16(4). e0249648–e0249648. 10 indexed citations
14.
Melosky, Barbara, Shantanu Banerji, Normand Blais, et al.. (2020). Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology. 27(2). 146–155. 17 indexed citations
15.
Laurie, Scott A., Shantanu Banerji, Normand Blais, et al.. (2019). Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology. 26(1). 81–93. 35 indexed citations
16.
Yip, Stephen, Anna Christofides, Shantanu Banerji, et al.. (2019). A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. Current Oncology. 26(2). 241–254. 34 indexed citations
17.
Banerji, Shantanu, et al.. (2018). P1.12-08 The Effect of Cisplatin Versus Carboplatin on Cancer Outcomes for Small Cell Lung Cancer Patients in a Population-Based Cohort. Journal of Thoracic Oncology. 13(10). S576–S576. 2 indexed citations
18.
Kim, Julian, et al.. (2017). P2.01-038 Discrimination of NSCLC Cases from Cancer-Free Controls and Adenocarcinoma from Squamous Cell Carcinoma Using Plasma Metabolomics Profiles. Journal of Thoracic Oncology. 12(1). S808–S809. 1 indexed citations
19.
Desautels, Danielle, et al.. (2015). Effect of FK866, NAMPT inhibitor, on small cell lung cancer cell lines.. Journal of Clinical Oncology. 33(15_suppl). e18562–e18562. 2 indexed citations
20.
Dooley, Alison L., Monte M. Winslow, Derek Y. Chiang, et al.. (2011). Nuclear factor I/B is an oncogene in small cell lung cancer. Genes & Development. 25(14). 1470–1475. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hong Jian Breakdown of academic impact, for papers by Rafał Stec Breakdown of academic impact, for papers by Jacques Raphael Breakdown of academic impact, for papers by Fernando Franco Breakdown of academic impact, for papers by Gwyn Bebb Breakdown of academic impact, for papers by Laurence Vanlemmens Breakdown of academic impact, for papers by Shipra Gandhi Breakdown of academic impact, for papers by Antonia Ridolfi Breakdown of academic impact, for papers by Maria Alice Franzoi Breakdown of academic impact, for papers by Keerthi Gogineni
Rankless by CCL
2026